Advances in the Treatment of Lung Adenocarcinoma with Dihydroartemisinin

肺腺癌作为临床高发的恶性肿瘤，其常规治疗方案包括化学治疗、放射治疗及分子靶向治疗，然而这些方法普遍存在疗效局限、毒副作用显著以及治疗费用高昂等问题。作为青蒿素类化合物的关键衍生物，双氢青蒿素在抗肿瘤领域展现出重要的研究价值。目前，该化合物在抗肿瘤作用机制的基础研究及临床转化方面已取得显著成果，为未来实现临床应用突破奠定了重要基础。中医药干预在肿瘤综合治疗中展现出独特优势，不仅能协同增强放化疗及靶向药物的治疗效果，还可显著降低治疗相关不良反应，改善耐药现象，从而有效提升患者生存质量并延长生存时间。Lung adenocarcinoma, as a clinically prevalent malignant tumor, has conventional treatment options including chemotherapy, radiotherapy, and molecular targeted therapy. However, these approaches commonly suffer from limited efficacy, significant toxic side effects, and high treatment costs. As a key derivative of artemisinin-derived compounds, dihydroartemisinin demonstrates significant research value in the field of anti-tumor therapy. Currently, fundamental research on its anti-tumor mechanisms and clinical translation has yielded notable achievements, laying a crucial foundation for future breakthroughs in clinical application. Traditional Chinese medicine interventions demonstrate unique advantages in comprehensive cancer treatment, not only synergistically enhancing the therapeutic effects of radiotherapy, chemotherapy, and targeted drugs but also significantly reducing treatment-related adverse reactions and improving drug resistance. Consequently, they effectively enhance patients’ quality of life and prolong survival time.